Literature DB >> 29247673

Tat-enhanced delivery of the C terminus of HDAg-L inhibits assembly and secretion of hepatitis D virus.

Hsiu-Chen Huang1, Hsu-Feng Lu2, Yu-Heng Lai3, Chung-Pei Lee4, Hui-Kang Liu5, Cheng Huang6.   

Abstract

Hepatitis D virus (HDV) contains a single-stranded circular RNA genome that encodes two forms of hepatitis delta antigen (HDAg), the small delta antigen (HDAg-S) and the large delta antigen (HDAg-L). The two proteins have an identical amino acid sequence, except that HDAg-L has a 19-amino-acid extension at the C terminus. The domain spanning amino acid residues 198-210 of the HDAg-L (HDAg-L(198-210)) contains a nuclear export signal (NES), which is important for the nuclear export of HDV ribonucleoprotein to the cytoplasm. In this study, we established a cell permeable TAT-HA-HDAg-L(198-210) fusion protein using an E. coli protein expression system, to determine its function during HDV infection. The cytotoxicity of the TAT-HA-HDAg-L(198-210) fusion protein was investigated using an MTT assay, while a GST pull-down assay revealed that the TAT-HA-HDAg-L(198-210) fusion protein interfered with the interaction between HDAg-L and clathrin heavy chain (CHC). In addition, the cellular distribution of HDAg-L, in the presence of HBsAg, was observed by immunofluorescence staining and the TAT-HA-HDAg-L(198-210) fusion protein was found to impede the nuclear export of HDAg-L. Furthermore, assembly of HDV virus-like particles (VLPs) was decreased by the expression of the TAT-HDAg-L(198-210) fusion protein. The TAT-HA-HDAg-L(198-210) fusion protein also inhibited virus particle assembly and HDV secretion in a mouse model. These results suggest that the TAT-HA-HDAg-L(198-210) fusion protein inhibits the nuclear export of HDAg-L and competes with the C terminus of HDAg-L for interaction with CHC, and may have potential as a therapeutic agent for HDV infection.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HDV assembly; Hepatitis delta antigen; Tat-enhanced delivery

Mesh:

Substances:

Year:  2017        PMID: 29247673     DOI: 10.1016/j.antiviral.2017.12.009

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  3 in total

Review 1.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

2.  Identification of a novel interaction site between the large hepatitis delta antigen and clathrin that regulates the assembly of genotype III hepatitis delta virus.

Authors:  Wei-Chung Chiou; Hsu-Feng Lu; Jui-Chieh Chen; Yu-Heng Lai; Ming-Fu Chang; Yuan-Li Huang; Ni Tien; Cheng Huang
Journal:  Virol J       Date:  2022-10-17       Impact factor: 5.913

3.  Cell-Penetrating Peptides-Based Liposomal Delivery System Enhanced Immunogenicity of Peptide-Based Vaccine against Group A Streptococcus.

Authors:  Jieru Yang; Farrhana Firdaus; Armira Azuar; Zeinab G Khalil; Nirmal Marasini; Robert J Capon; Waleed M Hussein; Istvan Toth; Mariusz Skwarczynski
Journal:  Vaccines (Basel)       Date:  2021-05-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.